The DISC assay: A cost-effective guide to treatment for chronic lymphocytic leukemia

International Journal of Technology Assessment in Health Care

Volumn 15, Issue 1, 1999, Pages 173-184

  Mason, James M ^a   Drummond, Michael F ^a   Bosanquet, Andrew G ^a   Sheldon, Trevor A ^a  

^a NONE

Author keywords

Antitumor; Chronic; Cost benefit analysis; Drug screening assays; Leukemia; Lymphocytic; Survival analysis

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; METHYLPREDNISOLONE; PENTOSTATIN; PREDNISOLONE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG DETERMINATION; DRUG EFFICACY; DRUG SCREENING; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0032964269     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462399152565     Document Type: Review

References (17)

1. Altman, D. G. Practical statistics for medical research. London: Chapman and Hall, 1991, chapter 13.
2. Best, L. Fludarabine in the treatment of chronic lymphocytic leukaemia. Report to the South and West Region Development and Evaluation Committee. Bristol: NHS Executive (South West), 1995.
3. Binet, J. L., Aiguier, A., Dighiero, G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from multivariate survival analysis. Cancer, 1981, 4, 198-206.
4. Bird, M. C., Bosanquet, A. G., Forskitt, S., & Gilby, E. D. Long-term comparison of results of a drug sensitivity assay in vitro with patient response in lymphatic neoplasms. Cancer, 1988, 61, 1104-09.
5. Bosanquet, A. G. Correlations between therapeutic response of leukemias and in-vitro drug-sensitivity assay. Lancet, 1991, 337, 711-14.
6. Bosanquet, A. G. Short term in vitro drug sensitivity for cancer chemotherapy. A summary of correlations of test results with patient response and survival. Forum Trends in Experimental and Clinical Medicine, 1994, 4, 179-95.
7. Bosanquet, A. G., & Bird, P. B. Enhanced in vitro drug sensitivity testing of chronic lymphocytic leukemia using refined DiSC assay methodology. Leukemia Research, 1996, 20, 143-53.
8. Bosanquet, A. G., & Bell, P. B. Novel in vitro analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in CLL. Blood, 1996, 87, 1962-71.
9. Catovsky, D., Fooks, J., & Richards, S. Prognostic factors in chronic lymphocytic leukemia: The importance of age, sex and response of treatment to survival. British Journal of Haematology, 1989, 72, 141-49.
10. Catovsky, D., Richards, S., Fooks, J., & Hamblin, T. J. CLL trials in the United Kingdom: The Medical Research Council CLL trials 1, 2 and 3. Leukemia and Lymphoma, 1991, S105-12.
11. Doubilet, P. D., Begg, C. B., Weinstein, M. C., Braun, P., & McNeil, B. J. Probabilistic sensitivity analysis using Monte Carlo simulation. Medical Decision Making, 1985, 5, 157-77.
12. Flinn, I. W., & Grever, M. R. Chronic lymphocytic leukemia. Cancer Treatment Reviews, 1996, 22, 1-23.
13. Iezzoni, L. I. (ed.). Risk adjustment for measuring health outcomes. Ann Arbor, MI: Health Administration Press, 1994.
14. Karmiris, T. D., Lister, T. A., & Rohatiner, A. Z. S. Chronic lymphocytic leukemia. British Journal of Hospital Medicine, 1991, 46, 379-85.
15. Schrek, R. Differences between responsive and intractable chronic lymphocytic leukemia. Medical Hypotheses, 1990, 31, 81-82.
16. Schrek, R. Essential in vitro test before treatment of patients with intractable chronic lymphocytic leukemia. Acta Haematologica, 1990, 84, 104-05.
17. Weatherall, D. J., Ledingham, J. G., & Warrell, D. A. (eds). Oxford Textbook of Medicine, 2nd ed. Oxford Medical Publications: Oxford, 1987.